PennyStockTrader2
1 year ago
Picked up 15K at .11 bidding more, I really feel that at this price its a steal with market cap of 4 million bucks, and the CEO has a great track record, no game played, never late on filings, etc. This just needs more time. Share structure continues to be excellent with majority held by CEO and partner restricted
Market Cap Market Cap
4,247,283
05/15/2023
Authorized Shares
1,000,000,000
05/15/2023
Outstanding Shares
38,263,813
05/15/2023
Restricted
29,444,232
05/15/2023
Unrestricted
8,819,581
05/15/2023
PennyStockTrader2
3 years ago
SIGY really amazes me to be honest. I mean these guys go by the book, they are on time with their filings, they are organized with their press releases with a ton of detail, and they are making good progress with their business plan, and the CEO is very accessible, etc. etc. etc.. Why the stock languishes between 50 cents to a buck with random sometimes nonexistent volume I have no idea, granted a lot, no most of the stock is locked with the founders, there should be enough left in the float to trade. That said, when the heavy hitter news does hit, hopefully in the next year, this should take off with little resistance, BUT there is also risk that anyone that does have shares will want to get out and re-allocate their capital. We'll have to see, but for now I would take opportunities to buy at 40 - 60 cents and sell around a buck or more if there is a spike, which with stocks like this can happen at any time, so best be prepared with GTC orders.
makinezmoney
4 years ago
$SIGY: InVitro-STUDY.... Sigyn-Therapy(TM) to adsorb viral pathogens including Covid-Sars
Sigyn Therapeutics(TM) Discloses In-Vitro Viral Pathogen Study
4:15 PM ET 4/21/21 | GlobeNewswire
Sigyn Therapeutics(TM) Discloses In-Vitro Viral Pathogen Study
Sigyn Therapy(TM) demonstrates the ability to address viral pathogens, including SARS-CoV-2 (COVID-19)
SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today disclosed initial in vitro study observations that demonstrated the ability of Sigyn Therapy(TM) to adsorb viral pathogens, including SARS-CoV-2 (COVID-19).
Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death. The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide. Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.
In the in vitro study, Sigyn reported the ability of the adsorbent components incorporated within Sigyn Therapy to address viral pathogens, including COVID-19. As the result of a two-hour exposure to Sigyn's adsorbent components, the presence of SARS-CoV-2 pseudotyped lentivirus was reduced by 68.8% from plasma. SARS-CoV-2 pseudotyped lentivirus is an established model previously utilized to study the development of antiviral drugs to treat COVID-19 and to assess the efficacy of vaccines against COVID-19 variants.
Sigyn Chairman and CEO, Jim Joyce stated: "While our first viral depletion observation may be compelling, we recognize this to be the first of several steps to validate viral depletion in combination with pro-inflammatory cytokine elimination as an effective strategy to mitigate virus-induced cytokine storms."
Sigyn Therapeutics further disclosed that it submitted a provisional patent application to the United States Patent and Trademark Office (USPTO) to protect this new discovery.
Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions. Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. The single-use medical device is designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide.
Since December 1, 2020, the Company has reported results from several in vitro studies designed to validate the capability of Sigyn Therapy to address a broad-spectrum of inflammatory targets.
Included among these studies was the simultaneous capture of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock. The dysregulated over-production of IL-1B, IL-6 and TNF-a can induce organ failure and cause death. An objective of this study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy. Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.
Sigyn Therapeutics has also reported the results of an in vitro pilot study that modeled the ability of Sigyn Therapy(TM) to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream. CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) participate in concert with freely circulating cytokines to further escalate Cytokine Storm Syndrome. CytoVesicles have previously been an elusive target as they can be 20-60 times larger than cytokines themselves. In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy's adsorbent components to deplete CytoVesicles from human blood plasma. After a two-hour interaction with Sigyn's adsorbent components, liposome concentrations in human blood plasma were reduced 90%. Previously published studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the similarity of their size and structural characteristics.
The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.
About Sigyn Therapeutics
Sigyn Therapeutics(TM) is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy(TM) is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn Therapeutics, Inc. ("Sigyn") that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "could," "will," "plan," "intend," "anticipate," "approximate," "expect," "potential," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn's future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn's expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn's business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn's business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity's ability to up-list to a national securities exchange, (viii) risks related to the combined entity's access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management's attention from Sigyn's ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn's views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn's views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com
> Dow Jones Newswires
April 21, 2021 16:15 ET (20:15 GMT)
AskMuncher
4 years ago
$SIGY Sigyn Therapeutics Announces Force Wealth Roundtable Forum with Goldman Small Cap Research
Press Release | 03/16/2021
The Event Occurs Tomorrow, March 17th at 12pm Eastern / 9am Pacific Time
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome, announced today that its Chairman and CEO, Jim Joyce, will participate in a “live” roundtable forum with Rob Goldman of Goldman Small Cap Research to discuss the science and clinical opportunities that underlie Sigyn Therapy™, a novel blood purification technology designed to treat sepsis and other life-threatening conditions that stem from cytokine storm syndrome.
This exclusive Force Family Office event occurs tomorrow, March 17, 2021 at 12:00pm Eastern Time / 9:00 am Pacific Time. Click on the following link to register for the event: https://forcewealth.com/portfolio-items/sigyn-03-17/?portfolioCats=28
About Sigyn Therapeutics
Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com
About Rob Goldman at Goldman Small Cap Research
Rob Goldman founded Goldman Small Cap Research in 2009. He leads the Firm's investment research strategy, and oversees a team of contractor analysts and editors, while serving as chief analyst. Rob has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund. As an investment manager, Rob's model portfolio was once ranked the 4th best small cap growth performer in the U.S. by Money Manager Review.
To learn more, visit www.goldmanresearch.com
About Force Family Office
FORCE works with Family Offices, Foundations, and Endowments by introducing them to leaders of public companies looking for open market buyers and privately held businesses at the capital acquisition stage. We’re constantly bringing unique opportunities and information to our community and make connections by actively seeking out best-in-class companies for introduction. In addition, our elite peer-to-peer community brings individuals, endowments and foundations together all over the world, facilitating both information sharing with symposiums, networking events, and conferences.
To learn more, visit www.forcewealth.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
Midwestrader
9 months ago
Renee
9 months ago
Emerging Growth Conf
3 years ago
iPickle
3 years ago
crudeoil24
4 years ago
